The correlation between the level of 25-hydroxyvitamin D [25(OH)D] and residency of multiple sclerosis patients in Montenegro – higher levels only in men in the north of the country
Abstract
Background/Aim. Multiple Sclerosis (MS) is a chronic neurological disease associated with low serum levels of 25-hydroxyvitamin D [25(OH)D]. The aim of this study was to determine the association between serum levels of 25(OH)D and the latitude as well as clinical MS severity and progression expressed by expanded disability status scale (EDSS) and multiple sclerosis severity score (MSSS). Methods. A total of 196 patients, from North and South of Montenegro, aged 18 to 65 years, with confirmed diagnosis of MS were recruited for the study. Serum samples were collected for 25(OH)D measurement. Control group consisted of 196 health controls, randomly selected from medical staff employed in health centers from three cities in North and Clinical Centre of Montenegro from the South. Results. The serum levels of 25(OH)D were significantly lower in MS patients compared to controls (p < 0.001). The serum levels of 25(OH)D were significantly different in regard to gender, with women showing lower levels. Although in the entire group of patients there was no statistical correlation between the levels of 25(OH)D and their residence, the significantly higher levels of 25(OH)D were detected in men from the North compared to women. The course of the disease had an impact on the 25(OH)D serum levels. 25(OH)D levels also significantly correlated with clinical parameters of both, disability (Spearman's r = -0.23, p = 0.001) and progression (Spearman's r = -0.25, p = 0.0004) of MS. Conclusion. Serum levels of 25(OH)D were associated with disability and progression in MS patients. Lower levels of 25(OH)D were detected in female patients from the North. The low level of 25(OH)D cannot be solely explained with unfavorable latitude and insufficient sun exposure, therefore further genetic analysis is needed.
References
Daroff RB, Fenichel GM, Jankovic J, Mazziotta JC. Bradley's Neu-rology in Clinical Practice. 6th ed. Philadelphia: Elsevier Saunders; 2012.
Pugliatti M, Sotgiu S, Rosati G. The worldwide prevalence of multiple sclerosis. Clin Neurol Neurosurg 2002; 104(3): 182−91.
van der Mei IA, Ponsonby AL, Dwyer T, Blizzard L, Simmons R, Taylor BV, et al. Past exposure to sun, skin phenotype, and risk of multiple sclerosis: Case-control study. BMJ 2003; 327(7410): 316.
Kampman MT, Brustad M. Vitamin D. A candidate for the environmental effect in multiple sclerosis: Observations from Norway. Neuroepidemiology 2008; 30(3): 140−6.
Cantorna MT. Vitamin D and multiple sclerosis: An update. Nutr Rev 2008; 66(10 Suppl 2): S135−8.
Dobson R, Giovannoni G, Ramagopalan S. The month of birth ef-fect in multiple sclerosis: Systematic review, meta-analysis and effect of latitude. J Neurol Neurosurg Psychiatr 2013; 84(4): 427−32.
Auer DP, Schumann EM, Kümpfel T, Gössl C, Trenkwalder C. Seasonal fluctuations of gadolinium-enhancing magnetic resonance imaging lesions in multiple sclerosis. Ann Neurol 2000; 47(2): 276−7.
Hayes CE, Hubler SL, Moore JR, Barta LE, Praska CE, Nashold FE. Vitamin D Actions on CD4 (+) T Cells in autoimmune disease. Front Immunol 2015; 6: 100.
Kragt JJ, van Amerongen BM, Killestein J, Dijkstra CD, Uitdehaag BM, Polman CH, et al. Higher levels of 25-hydroxyvitamin D are associated with a lower incidence of multiple sclerosis only in women. Mult Scler 2009; 15(1): 9−15.
Ascherio A, Munger KL, White R, Köchert K, Simon KC, Polman CH, et al. Vitamin D as an Early Predictor of Multiple Sclero-sis Activity and Progression. Vitamin D as an Early Predictor of Multiple Sclerosis Activity and Progression. JAMA Neurol 2014; 71(3): 306−14.
Weinstock-Guttman B, Zivadinov R, Qu J, Cookfair D, Duan X, Bang E, et al. Vitamin D metabolites are associated with clini-cal and MRI outcomes in multiple sclerosis patients. J Neurol Neurosurg Psychiatry 2011; 82(2): 189−95.
Smolders J, Menheere P, Kessels A, Damoiseaux J, Hupperts RR. Association of vitamin D metabolite levels with relapse rate and disability in multiple sclerosis. Mult Scler J 2008; 14(9): 1220−4.
McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50(1): 121−7.
Kurtzke JF. Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology 1983; 33(11): 1444−52.
Roxburgh RH, Seaman SR, Masterman T, Hensiek AE, Sawcer SJ, Vukusic S, et al. Multiple Sclerosis Severity Score. Using disa-bility and disease duration to rate disease severity. Neurology 2005; 7(64): 1144−51.
Hydrometeorological Institute of Montenegro. 2016. home-page on the Internet. [cited 2016 Feb 2]. Available from: http://www.meteo.co.me/misc.php?text=128&sektor=1
Soilu-Hänninen M, Airas L, Mononen I, Heikkilä A, Viljanen M, Hänninen A. 25-Hydroxyvitamin D levels in serum at the onset of multiple sclerosis. Mult Scler 2005; 11(3): 266–71.
Correale J, Ysrraelit MC, Gaitán MI. Immunomodulatory ef-fects of Vitamin D in multiple sclerosis. Brain 2009; 132(Pt 5): 1146−60.
Smolders J, Menheere P, Thewissen M, Peelen E, Tervaert JW, Hup-perts R, et al. Regulatory T cell function correlates with serum 25-hydroxyvitamin D, but not with 1,25-dihydroxyvitamin D, parathyroid hormone and calcium levels in patients with re-lapsing remitting multiple sclerosis. J Steroid Biochem Mol Bi-ol 2010; 121(1−2): 243−6.
Holick MF, Chen TC. Vitamin D deficiency: A worldwide problem with health consequences. Am J Clin Nutr 2008; 87(4): 1080S−6S.
Pierrot-Deseilligny C, Souberbielle JC. Is hypovitaminosis D one of the environmental risk factors for multiple sclerosis?. Brain 2010; 133(Pt 7): 1869−88.
Webb AR, Kline L, Holick MF. Influence of season and latitude of the cutaneous synthesis of vitamin D3: Exposure to winter sunlight in Boston and Edmonton will not promote vitamin D3 synthesis in human skin. J Clin Endocinol Metabol 1988; 67: 373−8.
Hatamian H1, Bidabadi E, Seyed Saadat SM, Saadat NS, Kazem-nezhad E, Ramezani H, et al. Is serum vitamin D levels asso-ciated with disability in patients with newly diagnosed multi-ple sclerosis?. Iran J Neurol 2013; 12(2): 41−6.
Hagenau T, Vest R, Gissel TN, Poulsen CS, Erlandsen M, Mosekilde L, et al. Global vitamin D levels in relation to age, gender, skin pigmentation and latitude: an ecologic meta-regression analysis. Osteoporos Int 2009; 20(1): 133−40.
Zadshir A, Tareen N, Pan D, Norris K, Martins D. The preva-lence of hypovitaminosis D among US adults: data from the NHANES III. Ethn Dis 2005; 15(4 Suppl 5): S5−97-101.
van der Mei IA, Ponsonby AL, Engelsen O, Pasco JA, Mcgrath JJ, Eyles DW, et al. The high prevalence of vitamin D insufficien-cy across Australian populations is only partly explained by season and latitude. Environ Health Perspect 2007; 115(8): 1132−9.
Rockell JE, Skeaff CM, Williams SM, Green TJ. Serum 25-hydroxyvitamin D concentrations of New Zealanders aged 15 years and older. Osteoporosis Int 2006; 17(2): 1382−9.
Langlois K, Greene-Finestone L, Little J, Hidiroglou N, Whiting S. Vitamin D status of Canadians as measured in the 2007 to 2009 Canadian Health Measures Survey. Health Rep 2010; 21(1): 47−55.
Välimäki VV, Löyttyniemi E, Välimäki MJ. Vitamin D fortification of milk products does not resolve hypovitaminosis D in young Finnish men. Eur J Clin Nutr 2007; 61(4): 493−7.
Linhares ER, Jones DA, Round JM, Edwards RH. Effect of nutrition on vitamin D status: Studies on healthy and poorly nourished Brazilian children. Am J Clin Nutr 1984; 39(4): 625−30.
Lips P. Worldwide status of vitamin D nutrition. J Steroid Biochem Mol Biol 2010; 121(1−2): 297−300.